Please use this identifier to cite or link to this item: http://hdl.handle.net/10662/19763
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSenovilla, Laura-
dc.contributor.authorVitale, Ilio-
dc.contributor.authorMartins, Isabelle-
dc.contributor.authorTailler, M-
dc.contributor.authorPailleret, C-
dc.contributor.authorMichaud, M-
dc.contributor.authorGalluzzi, Lorenzo-
dc.contributor.authorAdjemian, S-
dc.contributor.authorKepp, Oliver-
dc.contributor.authorNiso Santano, Mireia-
dc.contributor.authorShen, S-
dc.contributor.authorMariño García, Guillermo-
dc.contributor.authorCriollo, A-
dc.contributor.authorBoileve, A-
dc.contributor.authorJob, B-
dc.contributor.authorLadoire, S-
dc.contributor.authorGhiringhelli, François-
dc.contributor.authorSistigu, A-
dc.contributor.authorYamazaki, T-
dc.contributor.authorRello Varona, Santiago-
dc.contributor.authorLocher, C-
dc.contributor.authorPoirier Colame, V-
dc.contributor.authorTalbot, M-
dc.contributor.authorValent, A-
dc.contributor.authorBerardinelli, F-
dc.contributor.authorAntoccia, A-
dc.contributor.authorCiccosanti, F-
dc.contributor.authorFimia, G.M.-
dc.contributor.authorPiacentini, M-
dc.contributor.authorFueyo, A.-
dc.contributor.authorMessina, N.L.-
dc.contributor.authorLi, M-
dc.contributor.authorChan, C.J.-
dc.contributor.authorSigl, V.-
dc.contributor.authorPourcher, G-
dc.contributor.authorRuckenstuhl, C-
dc.contributor.authorCarmona-Gutierrez, D-
dc.contributor.authorLazar, V-
dc.contributor.authorPenninger, J.M.-
dc.contributor.authorMadeo, F-
dc.contributor.authorLopez-Otin, C-
dc.contributor.authorSmyth, M.J-
dc.contributor.authorZytvogel, L.-
dc.contributor.authorCastedo, M.-
dc.contributor.authorKroemer, Guido-
dc.date.accessioned2024-02-02T11:20:48Z-
dc.date.available2024-02-02T11:20:48Z-
dc.date.issued2012-
dc.identifier.urihttp://hdl.handle.net/10662/19763-
dc.description.abstractCancer cells accommodate multiple genetic and epigenetic alterations that initially activate intrinsic (cell-autonomous) and extrinsic (immune-mediated) oncosuppressive mechanisms. Only once these barriers to oncogenesis have been overcome can malignant growth proceed unrestrained. Tetraploidization can contribute to oncogenesis because hyperploid cells are genomically unstable. We report that hyperploid cancer cells become immunogenic because of a constitutive endoplasmic reticulum stress response resulting in the aberrant cell surface exposure of calreticulin. Hyperploid, calreticulin-exposing cancer cells readily proliferated in immunodeficient mice and conserved their increased DNA content. In contrast, hyperploid cells injected into immunocompetent mice generated tumors only after a delay, and such tumors exhibited reduced DNA content, endoplasmic reticulum stress, and calreticulin exposure. Our results unveil an immunosurveillance system that imposes immunoselection against hyperploidy in carcinogen- and oncogene-induced cancers.es_ES
dc.description.abstractLas células cancerosas albergan múltiples alteraciones genéticas y epigenéticas que activan inicialmente mecanismos oncosupresores intrínsecos (autónomos de la célula) y extrínsecos (mediados por el sistema inmunitario). Sólo una vez superadas estas barreras a la oncogénesis puede el crecimiento maligno proceder sin restricciones. La tetraploidización puede contribuir a la oncogénesis porque las células hiperploides son genómicamente inestables. Hemos descubierto que las células cancerosas hiperploides se vuelven inmunogénicas debido a una respuesta de estrés constitutiva del retículo endoplásmico que da lugar a una exposición aberrante de la calreticulina en la superficie celular. Las células cancerosas hiperploides expuestas a la calreticulina proliferaron fácilmente en ratones inmunodeficientes y conservaron su mayor contenido de ADN. Por el contrario, las células hiperploides inyectadas en ratones inmunocompetentes generaron tumores sólo después de un retraso, y dichos tumores mostraron un contenido reducido de ADN, estrés del retículo endoplásmico y exposición a la calreticulina. Nuestros resultados desvelan un sistema de inmunovigilancia que impone la inmunoselección contra la hiperploidía en cánceres inducidos por carcinógenos y oncogenes.es_ES
dc.description.sponsorshipWe are grateful to M. L. Albert (Institut Pasteur, Paris) for Ifnar1−/− and Ifng−/− mice, M. Colonna (Washington University School of Medicine, St. Louis, MO) for Cd226−/− mice (Dnam-1−/− mice), S. B. Horwitz (Albert Einstein College of Medicine, New York) for epothilone B–resistant A549 cells, R. Prywes (Columbia University, New York) for the GFP-ATF6–encoding plasmid, J. Yuan (Massachusetts Institute of Technology, Boston) for the XBP1-DBD-Venus–encoding construct, T. Reid (NIH, Bethesda, MD) for DLD-1 and DLD1+7 cell lines, and D. Metivier for assistance with fluorescence-activated cell sorting (FACS) experiments. G.K. is supported by the Ligue Nationale contre le Cancer (LNC, Equipe labelisée), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain), Fondation pour la Recherche Médicale (FRM), Institut National du Cancer (INCa), Cancéropôle Ile-de-France, Fondation Bettencourt-Schueller, and the LabEx Immuno-Oncology. F.M. is grateful to the Fonds Zur Förderung der Wissenschaftlichen Forschung (FWF, grants LIPOTOX, P23490-B12, P24381-B20, and W 1226-B18). L.S. and M.M. are supported by FRM. I.V., I.M., M.T., and S.A. are supported by LNC. M.N.-S. is supported by a postdoctoral contract of Junta de Extremadura (Spain) and G.M. by European Molecular Biology Organization. M.J.S. was supported by National Health and Medical Research Council (NH and MRC) Australia and the Victorian Cancer Agency. C.J.C. was supported by Leukemia Foundation of Australia, Monash University. N.M. was supported by Cancer Research Institute. J.M.P. and V.S. are supported by the Austrian Academy of Sciences, an Advanced European Research Council grant, and the European Union INFLA-CARE network. L.S., I.V., I.M., M.T., C.P., M.M., S.A., O.K., M.N.-S., S.S., G.M., A.C., A.B., B.J., S.L., F.G., A.S., T.Y., S.R.-V., C.L., V.P.-C., M.T., A.V., F.B., A.A., F.C., G.M.F., M.P., A.F., N.L.M., M.L., C.J.C., V.S., G.P., V.L., J.M.P., C.L.-O., M.J.S., and M.C. performed experiments. L.S., C.R., D.C.-G., F.M., L.Z., M.C., and G.K. designed the study. L.S., L.Z., M.C., and G.K. analyzed results. L.S., L.G., and G.K. assembled the figures and wrote the paper. The authors declare no conflicts of interest. L.D.W. and M.K. were funded by NIH grants R01HG004037 and RC1HG005334 and NSF CAREER grant 0644282. Data from the ENCODE consortium are available from the UCSC Genome Browser at http://genome.ucsc.edu/ENCODE, and data from the 1000 Genomes Project is available at www.1000genomes.org/data. ENCODE annotations, mammalian constraint, human diversity, background selection, and filtering information for every SNP and every human nucleotide are available at http://compbio.mit. edu/human-constraint. L.D.W. and M.K. designed the study, analyzed data, and wrote the paper.-
dc.format.extent8 p.es_ES
dc.format.mimetypeapplication/pdfen_US
dc.language.isoenges_ES
dc.publisherAmerican Association for the Advancement of Science-
dc.subjectCánceres_ES
dc.subjectcanceren_US
dc.subjectHiperploidíaes_ES
dc.subjectHyperploiden_US
dc.subjectInmunovigilanciaes_ES
dc.subjectImmunosurveillanceen_US
dc.titleAn immunosurveillance mechanism controls cancer cell ploidyen_US
dc.typearticlees_ES
dc.description.versionpeerReviewedes_ES
europeana.typeTEXTen_US
dc.rights.accessRightsclosedAccesses_ES
dc.subject.unesco32 Ciencias Médicases_ES
europeana.dataProviderUniversidad de Extremadura. Españaes_ES
dc.identifier.bibliographicCitationSenovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., Shen, S., Mariño, G., Criollo, A., Boilève, A., Job, B., Ladoire, S., Ghiringhelli, F., Sistigu, A., Yamazaki, T., Rello-Varona, S., Locher, C., Poirier-Colame, V., Talbot, M., Valent, A., Berardinelli, F., Antoccia, A., Ciccosant,i F., Fimia, G.M., Piacentini, M., Fueyo, A., Messina, N.L., Li, M., Chan, C.J., Sigl, V., Pourcher, G., Ruckenstuhl, C., Carmona-Gutierrez, D., Lazar, V., Penninger, J.M., Madeo, F., López-Otín, C., Smyth, M.J., Zitvogel, L., Castedo, M., Kroemer, G. (2012). An immunosurveillance mechanism controls cancer cell ploidy. Science, 6102(337), 1678-1684. https://doi.org/10.1126/science.1224922es_ES
dc.type.versionpublishedVersiones_ES
dc.contributor.affiliationUniversidad de Extremadura. Departamento de Bioquímica, Biología Molecular y Genéticaes_ES
dc.contributor.affiliationUniversité Paris-Sud. Francia-
dc.contributor.affiliationUniversità degli Studi Roma Tre. Italia-
dc.contributor.affiliationUniversità degli Studi di Roma Tor Vergata. Italia-
dc.contributor.affiliationUniversidad de Oviedo-
dc.contributor.affiliationUniversity of Melbourne. Australia.-
dc.contributor.affiliationUniversité Paris-Sorbonne (Paris V). France-
dc.relation.publisherversionhttps://www.science.org/doi/10.1126/science.1224922es_ES
dc.identifier.doi10.1126/science.1224922-
dc.identifier.publicationtitleSciencees_ES
dc.identifier.publicationissue337es_ES
dc.identifier.publicationfirstpage1678es_ES
dc.identifier.publicationlastpage1684es_ES
dc.identifier.publicationvolume6102es_ES
dc.identifier.orcid0000-0002-6506-422Xes_ES
Appears in Collections:DBYBM - Artículos

Files in This Item:
File Description SizeFormat 
science_1224922.pdf
???org.dspace.app.webui.jsptag.ItemTag.accessRestricted???
1,56 MBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons